Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Periostin contributes to differential sex-linked gene expression during infarct healing.

American journal of physiology. Heart and circulatory physiology·2026
Same author

The role of fibrosis in the pathophysiology of muscular dystrophy.

American journal of physiology. Cell physiology·2023
Same author

Scleraxis and fibrosis in the pressure-overloaded heart.

European heart journal·2022
Same author

NF-κB p65 Attenuates Cardiomyocyte PGC-1α Expression in Hypoxia.

Cells·2022
Same author

Canadian Contributions in Fibroblast Biology.

Cells·2022
Same author

Regulation of Cardiac Fibroblast GLS1 Expression by Scleraxis.

Cells·2022

Related Experiment Video

Updated: Mar 6, 2026

Assessing Cardiac Reprogramming using High Content Imaging Analysis
06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

1.5K

A primer on current progress in cardiac fibrosis.

Danah Al Hattab1,2, Michael P Czubryt1,2

  • 1a Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, 351 Tache Avenue, Winnipeg, MB R2H 2A6, Canada.

Canadian Journal of Physiology and Pharmacology
|March 9, 2017
PubMed
Summary

Cardiac fibrosis, a condition increasing heart stiffness and mortality in cardiovascular disease, lacks specific treatments. New research directions offer hope for novel therapies targeting fibrosis amelioration alongside existing treatments.

Keywords:
cardiac fibrosisextracellular matrixfibroblastfibroblastefibrose cardiaquefibrosis therapymatrice extracellulairemyofibroblastmyofibroblastetraitement de la fibrose

More Related Videos

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.8K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

Assessing Cardiac Reprogramming using High Content Imaging Analysis
06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

1.5K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.8K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K

Area of Science:

  • Cardiology
  • Pathology
  • Biomedical Research

Background:

  • Cardiac fibrosis is a major contributor to cardiovascular disease severity and patient mortality.
  • It involves excessive extracellular matrix deposition, leading to myocardial stiffness and impaired heart function.
  • Current cardiovascular disease treatments do not specifically address cardiac fibrosis, representing a significant clinical gap.

Purpose of the Study:

  • To provide an overview of cardiac fibrosis development.
  • To discuss emerging research avenues for novel anti-fibrotic therapies.
  • To highlight the need for treatments that complement existing cardiovascular disease management.

Main Methods:

  • Literature review and synthesis of current research on cardiac fibrosis.
  • Analysis of emerging therapeutic strategies and research directions.
  • Discussion of the pathological mechanisms underlying cardiac fibrosis.

Main Results:

  • Cardiac fibrosis exacerbates conditions like myocardial infarction, cardiomyopathy, and diabetes.
  • Fibrosis impairs both systolic and diastolic heart function and promotes arrhythmias.
  • Existing cardiovascular disease treatments do not target fibrosis directly.

Conclusions:

  • Cardiac fibrosis is a critical pathological process and a risk factor in cardiovascular disease.
  • There is an urgent need for specific treatments to ameliorate cardiac fibrosis.
  • Emerging research offers potential for new therapeutic strategies to improve patient outcomes.